Is hydropathic complementarity involved in antigen-antibody binding? 1995

D Boquet, and O Déry, and Y Frobert, and J Grassi, and J Y Couraud
CEA, Service de Pharmacologie et d'Immunologie, Gif-sur-Yvette, France.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000937 Antigen-Antibody Reactions The processes triggered by interactions of ANTIBODIES with their ANTIGENS. Antigen Antibody Reactions,Antigen-Antibody Reaction,Reaction, Antigen-Antibody,Reactions, Antigen-Antibody
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D013373 Substance P An eleven-amino acid neurotransmitter that appears in both the central and peripheral nervous systems. It is involved in transmission of PAIN, causes rapid contractions of the gastrointestinal smooth muscle, and modulates inflammatory and immune responses. Euler-Gaddum Substance P,Hypothalamic Substance P,SP(1-11),Euler Gaddum Substance P,Substance P, Euler-Gaddum,Substance P, Hypothalamic

Related Publications

D Boquet, and O Déry, and Y Frobert, and J Grassi, and J Y Couraud
March 2012, Journal of computational biology : a journal of computational molecular cell biology,
D Boquet, and O Déry, and Y Frobert, and J Grassi, and J Y Couraud
May 1984, Biochemical and biophysical research communications,
D Boquet, and O Déry, and Y Frobert, and J Grassi, and J Y Couraud
January 2001, Current topics in microbiology and immunology,
D Boquet, and O Déry, and Y Frobert, and J Grassi, and J Y Couraud
January 2021, Frontiers in molecular biosciences,
D Boquet, and O Déry, and Y Frobert, and J Grassi, and J Y Couraud
July 2023, Bioinformatics (Oxford, England),
D Boquet, and O Déry, and Y Frobert, and J Grassi, and J Y Couraud
January 1988, Proceedings of the National Academy of Sciences of the United States of America,
D Boquet, and O Déry, and Y Frobert, and J Grassi, and J Y Couraud
August 1989, The Journal of biological chemistry,
D Boquet, and O Déry, and Y Frobert, and J Grassi, and J Y Couraud
March 1995, Pharmaceutica acta Helvetiae,
D Boquet, and O Déry, and Y Frobert, and J Grassi, and J Y Couraud
October 1988, Journal of immunology (Baltimore, Md. : 1950),
D Boquet, and O Déry, and Y Frobert, and J Grassi, and J Y Couraud
March 1982, Pharmacological reviews,
Copied contents to your clipboard!